Whole-Brain Quantification of BBB-Targeted Biologics Using a Humanized TfR1 (hTFRC) Mouse Model (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR066.04 / FF8; Pres time: Nov 15, 2026; 08:00 AM - 12:00 PM; Location: WCC Halls A-C; "Using this model, we combined whole-organ 3D light-sheet fluorescence microscopy (LSFM) with AI-based image analysis to map the biodistribution of four clinically relevant biologics: Trontinemab and Tividenofusp alfa (TfR1-targeted), and Gantenerumab and Efavaleukin alfa (non-TfR-binding controls). This study establishes 1) the hTFRC mouse model as an adequate mouse model system to test biologics and 2) an LSFM and AI-driven platform for unbiased whole-organ biodistribution analysis. Together, this approach allows for simultaneous assessment of BBB transport efficiency, regional brain exposure, and peripheral liabilities to support the design of next-generation BBB-penetrant biologics."
Preclinical • CNS Disorders • CD31 • PECAM1 • TFRC
|
|
A. VICKERS1; M. JACOBSON1; M. ROQUE2; Y. LIU2; A. BUTT2; S. R. STERLACE1; L. GRIFFIN1; J. R. RICHARDSON1; H. H. HANSEN2; Y. GALLERO-SALAS2; U. ROOSTALU2
|